[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100626586":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":11,"centralContacts":35,"locations":41,"responsibleParty":61,"collaborators":11,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":65,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":11,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":84,"overallStatus":44,"whyStopped":11,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"Hudson Biotech","INDUSTRY",[8,16],{"label":9,"type":10,"description":11,"interventionNames":12},"Melanotan II + NB-UVB phototherapy","EXPERIMENTAL",null,[13,14,15],"Drug: Melanotan II (MT-II)","Drug: Placebo","Procedure: Narrowband UV-B (NB-UVB) phototherapy",{"label":17,"type":18,"description":11,"interventionNames":19},"Placebo + NB-UVB phototherapy","PLACEBO_COMPARATOR",[13,14,15],[21,26,30],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":11},"DRUG","Melanotan II (MT-II)","administered per protocol",[9,17],{"type":22,"name":27,"description":28,"armGroupLabels":29,"otherNames":11},"Placebo","matched, administered per protocol.",[9,17],{"type":31,"name":32,"description":33,"armGroupLabels":34,"otherNames":11},"PROCEDURE","Narrowband UV-B (NB-UVB) phototherapy","standardized schedule per site protocol",[9,17],[36],{"name":37,"role":38,"phone":39,"phoneExt":11,"email":40},"Seni S Lu, Phd","CONTACT","+86 13076790030","Seni-Lu@beijing-biotech.com",[42],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Peking University Shenzhen Hospital","RECRUITING","Shenzhen","Guangdong","518036","China","CN",{"type":51,"coordinates":52},"Point",[53,54],114.0683,22.54554,{"lat":54,"lon":53},[57],{"name":58,"role":38,"phone":59,"phoneExt":11,"email":60},"Zhen J Peng, Phd","+86 13076790039","Zhen-Peng@beijing-biotech.com",{"type":62,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100626586","phase-2-melanotan-ii-mt-ii-as-an-adjunct-to-nb-uvb-phototherapy-for-repigmentation-in-stable-nonsegmental-vitiligo-100626586",false,"NCT07437560","Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo","A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Melanotan II (Synthetic Cyclic Melanocortin Receptor Agonist) as an Adjunct to Narrowband UV-B Phototherapy in Adults With Stable Nonsegmental Vitiligo","MTII-VIT","Inclusion Criteria:\n\n* Adults aged 18-65 years able to provide informed consent.\n* Clinical diagnosis of nonsegmental vitiligo with stable disease (no new lesions and no lesion expansion) for \\>=6 months prior to screening.\n* Total body surface area involvement between 3% and 20% (inclusive), with at least two measurable target lesions suitable for standardized photography and colorimetry.\n* Willingness to undergo NB-UVB phototherapy per protocol and to avoid non-study vitiligo treatments during the study.\n* For participants of childbearing potential: agreement to use effective contraception during the study and for a protocol-specified period after the last dose.\n\nExclusion Criteria:\n\n* Segmental vitiligo as the predominant type, or rapidly progressive disease within the past 6 months.\n* Use of systemic immunosuppressive therapy, systemic corticosteroids, or JAK inhibitors within 8 weeks prior to screening (time windows may vary by drug\u002Fclass).\n* Use of topical calcineurin inhibitors or topical corticosteroids on target lesions within 2 weeks prior to baseline.\n* Prior treatment with afamelanotide or melanotan (including Melanotan II) within 6 months prior to baseline.\n* History of melanoma, dysplastic nevus syndrome, or other high-risk skin cancer history requiring close surveillance, as judged by the investigator.\n* Clinically significant uncontrolled hypertension, cardiovascular disease, or any condition that, in the investigator's judgment, increases risk with melanocortin agonist exposure.\n* Pregnant or breastfeeding.\n* Known hypersensitivity to study product components.\n* Participation in another interventional clinical trial within 30 days prior to screening.","ALL","18 Years","65 Years",{"count":75,"type":76},60,"ESTIMATED","INTERVENTIONAL",[79],"PHASE2","This example interventional study record describes a randomized Phase 2 clinical trial evaluating investigational Melanotan II (MT-II) as an adjunct to standard NB-UVB phototherapy for repigmentation in adults with stable nonsegmental vitiligo.",[82,83],"NonSegmental Vitiligo","Nonsegmental Vitiligo (Stable)",[85,86,87,88,89,90,91,92,93,94],"Melanotan II","MT-II","melanocortin receptor agonist","MC1R","melanogenesis","skin pigmentation","repigmentation","vitiligo","narrowband UV-B","phototherapy","2026-02-22",{"date":97,"type":98},"2026-02-27","ACTUAL",{"date":100,"type":98},"2026-02-02",{"date":102,"type":76},"2028-02-17",{"name":5,"class":6},1]